European Journal of Clinical Microbiology & Infectious Diseases

Papers
(The H4-Index of European Journal of Clinical Microbiology & Infectious Diseases is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Evaluation of metagenomic next-generation sequencing (mNGS) combined with quantitative PCR: cutting-edge methods for rapid diagnosis of non-invasive fungal rhinosinusitis69
Correction to: Added diagnostic value of 16S rRNA gene pan-mycobacterial PCR for nontuberculous mycobacterial infections: a 10-year retrospective study50
Retrospective and prospective evaluation of the FluoroType®-Mycobacteria VER 1.0 assay for the identification of mycobacteria from cultures in a French center46
Real-time recombinase-aided amplification assay for rapid amplification of the IS1081 gene of Mycobacterium tuberculosis44
Multicenter interlaboratory study of routine systems for the susceptibility testing of temocillin using a challenge panel of multidrug-resistant strains43
Household transmission of SARS-CoV-2 infection in the Paris/Ile-de-France area40
Impact of posaconazole prophylaxis and antifungal treatment on BAL GM performance in hematology malignancy patients with febrile neutropenia: a real life experience40
VanA-Enterococcus faecalis in Poland: hospital population clonal structure and vanA mobilome32
A previously documented Neisseria macacae isolate providing a false-positive result with Roche cobas 4800 CT/NG does not cross-react with the later generation cobas 6800 CT/NG assay28
Understanding bacterial diversity, infection dynamics, prevention of antibiotic resistance: an integrated study in an Algerian hospital context26
Incidence trends and epidemiology of invasive device-associated bacteremia in French nursing home residents, 2020–2024: Insights from the SPIADI Prospective Multicenter Study25
In-vitro activity of the novel β-lactam/β-lactamase inhibitor combinations and cefiderocol against carbapenem-resistant Pseudomonas spp. clinical isolates collected in Switzerland in 202225
Antimicrobial activities of aztreonam-avibactam and comparator agents tested against Enterobacterales from European hospitals analysed by geographic region and infection type (2019–2020)25
COVID-19 evolution in pediatric emergency department patients in Madrid, Spain: a single-center, retrospective study25
Extensively drug-resistant Haemophilus influenzae isolated in Geneva, Switzerland24
Antibiotic practices in kidney transplant recipients with urosepsis are associated with treatment outcomes – a post-hoc analysis of an observational study24
Prevalence and risk factors of extended-spectrum beta-lactamase producing E. coli causing urinary tract infections in Iceland during 2012–202124
Derivation and validation of a predictive mortality model of in-hospital patients with Acinetobacter baumannii nosocomial infection or colonization24
Real-world experience with meropenem/vaborbactam for the treatment of infections caused by ESBL-producing Enterobacterales and carbapenem-resistant Klebsiella pneumoniae23
Iron serum levels and iron homeostasis parameters in patients with nosocomial pneumonia treated with cefiderocol: post hoc analysis of the APEKS-NP study23
Antimicrobial use, healthcare-associated infections, and bacterial resistance in general hospitals in China: the first national pilot point prevalence survey report22
Efficacy analysis of intraventricular/intrathecal polymyxin B sulphate injections in the treatment of Post-neurosurgical CNS infections in neurocritical ill patients: a prospective observational study21
Evolving patterns of healthcare-associated infections in NICU: a five-year retrospective analysis from a tertiary children’s hospital in China21
Does selective digestive decontamination (SDD) increase antibiotic resistance? Long-term comparison of two intensive care units (with and without SDD) of the same tertiary hospital21
“Catheter replacement in catheter-associated urinary tract infection: current state of evidence “21
Increasing usage of chlorhexidine in health care settings: blessing or curse? A narrative review of the risk of chlorhexidine resistance and the implications for infection prevention and control21
0.16730403900146